DNMT1 and cancer: Decitabine, a DNMT1 inhibitor, depletes DNMT1 through proteasomal degradation.[36] Similar to DNMT1 knockdown, Decitabine treatment itself and together with NNMT overexpression has an additive effect on reducing cancer cell (NCI‐H82 and G‐401) sensitivities to OXPHOS inhibitors, Gboxin, Oligomycin A, and Berberine, (Figure 4K–M; Figure S5H–J, Supporting Information).